Lundbeck, MultiCell Ink Supply Agreement

Lundbeck Pharmaceuticals Italy and MultiCell Technologies have entered into a long-term agreement for the supply of one of the active components of MCT-125, MultiCell's investigational drug for the treatment of chronic fatigue in patients with multiple sclerosis (MS).

In a 138-patient, double-blind, placebo-controlled Phase II trial conducted in the UK by Amarin, MCT-125 demonstrated efficacy in significantly reducing the levels of fatigue in MS patients. The drug demonstrated effectiveness within four weeks of the first daily oral dosing and showed efficacy in all MS patient subpopulations, including relapsing-remitting, secondary progressive and primary progressive. Patients reported few if any side effects.

"We are pleased to have the opportunity to work with an outstanding company like Lundbeck Pharmaceuticals Italy, and look forward to a long-term relationship," Stephen Chang, president and CEO of MultiCell, said. "This contract is enabling, and helps us advance MCT-125 toward commencement of our planned Phase IIb human clinical trials."

Lundbeck Pharmaceuticals Italy manufactures proprietary active pharmaceutical ingredients and intermediates for the pharmaceutical and life science industries. The company also offers contract manufacturing services to many large multinational pharmaceutical companies.